The director of the Center for Neurological Restoration at Cleveland Clinic provided an inside perspective on how the MANAGE-PD tool can effectively assist in the Parkinson disease screening process.
"The second challenge is that advanced therapies, in particular device aided therapies, have a window [in which] we can optimally offer for our patients. If it’s too far advanced, then they lose the benefit of doing it altogether.”
In an effort to evaluate care gaps in patients with Parkinson disease (PD), Hubert Fernandez, MD, and colleagues used MANAGE-PD, a validated tool developed to support clinical decision-making in timely management of PD-related symptoms. Using an analytical sample of 2709 patients with PD, the tool grouped them into 3 categories: (1) adequately controlled on oral therapy; (2) inadequately controlled on oral therapy but oral optimization possible; and (3) inadequately controlled on oral therapy and eligible for device-aided therapies.
The data, presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, April 17-22, show that 19% of patients were adequately controlled on oral therapy and eligible for device-aided therapies. Notably, in the category of patients deemed eligible for device-aided therapies, 50% reported they did not have any discussion with providers about future device-aided therapies.
Fernandez, director of the Center for Neurological Restoration at Cleveland Clinic, said that this is a huge problem within the PD space and can have lasting effects if not properly addressed. In an interview with NeurologyLive, he discussed the MANAGE-PD tool in detail, along with the advantages it brings and the importance of improving PD screening.
For more coverage of AAN 2021, click here.